Pfizer counters patent cliff with 32% revenue growth from recent launches and acquisitions
PFE Pfizer Inc
$27.40 -0.51%
View chart & analysis → - 1Pfizer's revenue from recent launches and acquisitions grew by 32% in the third quarter of 2026.
- 2Pfizer secured $1.8 billion in cash and $12.4 billion in short-term investments in the third quarter of 2026.
- 3Management supports dividends based on Pfizer's 85% cash dividend payout ratio.
So what's the key point?
Revenue from Pfizer's new or acquired drugs grew by 32%. The company holds significant cash to support dividend payments to shareholders.
Source The Motley Fool +1 · View original ↗
Nothing hidden: past picks and how they did against the S&P 500.